Compare Crispr Therapeutics AG (CRSP) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Symbotic Inc — how do they compare? Crispr Therapeutics AG trades at $51 (market cap $4.97B), while Symbotic Inc trades at $43.63 (market cap $5.55B). The key difference: Crispr Therapeutics AG and Symbotic Inc are close in size by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | SYM | |
|---|---|---|
Market Cap | $4.97B | $5.55B |
Sector | Health | Technology |
52-Week High | $76.78 | $87.30 |
52-Week Low | $44.34 | $38.57 |
Enterprise Value | $3.32B | $3.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Symbotic Inc. (SYM) trades at $42.43, down 2.77% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $2.25 billion in 2025 but posted a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights the acquisition of ARMS Innovations, expanding its AI-powered warehouse optimization solutions. Analyst consensus remains positive with a $57.50 price target, but mixed earnings performance and high valuation ratios present challenges.
Outlook: SYM shows potential in the growing robotics and automation sector, supported by strong operating cash flow and strategic acquisitions. However, profitability concerns, high EV/EBITDA of 240.06, and competitive pressures pose significant risks. Investors should weigh the bullish analyst sentiment against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
